Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Medical Education and AI with Lloyd B. Minor
The Path of a Healthtech CTO with Margaret McKenna
The AI-Flipped Clinic with Zak Kohane
Putting the Pro in Provider Networks with Dan Rosenthal
The Exec Hiring Playbook with Ben Horowitz and Ali Ghodsi
Drugging the Undruggable with Greg Verdine
Forecasting Human Health with Jeffrey Kaditz
Will AI Kill Us All? with Marc Andreessen
AI, Innovation, and Regulatory Insights with Amy Abernethy
From Faculty to Founder: Building Startups from Academia
Curing the Trust Problem with Mark Cuban
The Founders Reinventing Healthcare with Fintech
Adapting Biopharma to AI with Greg Meyers
Healthcare x Fintech with Julie Yoo and David Haber
Journal Club: Engineering Logic into CAR T Therapies with Robbie Majzner
The Future of Cheese with Magi Richani
Reengineering Healthcare and Medicine with Technology with Vineeta Agarwala
Bio x American Dynamism with Katherine Boyle and David Ulevitch
Shaping Channel Partnerships with Sean Duffy
Strategizing Channel Partnerships with Florian Otto
Create your
podcast in
minutes
It is Free